前列腺癌的向阿尔法疗法:临床实践中可用的药物的审查
Honest Ndlovu1,2, Ismaheel O Lawal2,3, Joseph Kabunda1,2
1Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa.
概括
向性阿尔法疗法 (TAT) 在前列腺癌中显示出强有力的结果,优于其他辐射类型. 研究探讨了当前和新兴的TAT药物,包括针对PSMA阴性瘤的药物.
科学领域:
- 在瘤学瘤学.
- 核医学就是核医学.
- 放射性药物疗法是一种放射性药物疗法.
背景情况:
- 向性阿尔法疗法 (TAT) 在治疗激素敏感性和割抵抗性前列腺癌方面显示出显著的前景.
- TAT强大的放射生物特性比传统的电离辐射具有优势,包括已批准的剂[177Lu]Lu-PSMA-617.
- 目前的TAT临床应用主要针对前列腺特异性膜抗原 (PSMA).
研究的目的:
- 审查目前针对前列腺癌的有针对性的阿尔法疗法 (TAT) 药物.
- 探索新兴和临床前的TAT药物,包括那些针对PSMA阴性前列腺癌的药物.
- 为了比较各种TAT剂的疗效和潜力.
主要方法:
- 对现有TAT药物的临床试验数据和同情使用案例的审查.
- 对针对PSMA和非PSMA抗原的新型TAT剂的临床前研究分析.
- 放射生物特性和临床结果的比较评估.
主要成果:
- 在前列腺癌的不同阶段和治疗状态下,TAT有效.
- 针对PSMA的TAT剂被广泛使用,但对PSMA阴性疾病的替代品正在出现.
- [223Ra]RaCl2已被批准用于骨疼痛缓解,其他非PSMA向剂正在研究中.
结论:
- 向性阿尔法疗法是前列腺癌的一种非常有前途的治疗方式.
- 需要对各种TAT药物进行进一步的研究,包括针对PSMA阴性瘤的药物.
- 与其他辐射疗法相比,TAT具有更高的功效,因此需要继续进行临床开发.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
995
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
995
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.1K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.1K